Biolidics Ltd. (SG:8YY)
SGX:8YY
Want to see SG:8YY full AI Analyst Report?
8YY Stock Chart & Stats
S$0.04
<S$0.01(3.70%)
At close: 4:00 PM EST
S$0.04
<S$0.01(3.70%)
Day’s Range― - ―
52-Week RangeS$0.02 - S$0.09
Previous CloseN/A
Volume13.75M
Average Volume (3M)412.95K
Market Cap
S$78.00M
Enterprise ValueS$79.86M
Total Cash (Recent Filing)S$557.00K
Total Debt (Recent Filing)S$2.41M
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,733,441,800
10 Day Avg. Volume410,990
30 Day Avg. Volume412,950
Financial Highlights & Ratios
PEG Ratio0.66
Price to Book (P/B)58.30
Price to Sales (P/S)16.93
P/FCF Ratio-247.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue ReboundA ~197% revenue increase to ~5.3m in 2025 signals tangible commercial traction after a low base. Sustained top-line growth can enable scale benefits, improve absorption of fixed costs, and create a platform for durable margin recovery and expanded installed-base driven recurring sales.
Recurring Consumables ModelThe business model centers on test kits and consumables that create repeatable revenue per installed user. A growing installed base can produce predictable, high-frequency revenue streams, improving lifetime customer value and margin stability if commercialization and customer retention remain durable.
Improving Cash Flow TrendThe marked reduction in cash outflows from ~-2.3m to ~-0.36m in 2025 shows operational improvement and progress toward breakeven cash generation. Continued improvement would materially lower financing reliance and support reinvestment, making the business model more self-sustaining over months.
Bears Say
Persistent LossesChronic net losses (including a ~4.0m loss in 2025) indicate the company has not reached profitable scale. Persistent unprofitability erodes reserves, increases funding needs, and constrains the ability to invest in R&D or commercial expansion without dilutive financing or debt, risking long-term viability.
Weak Cash GenerationNegative operating and free cash flows across reporting periods show the business cannot self-fund growth yet. That structural cash deficit forces dependence on external capital, increasing execution risk if capital access tightens and limiting ability to pursue multi-quarter commercialization or scale-up initiatives.
Leverage & Thin Equity CushionMeaningful leverage relative to a small equity base and prior periods of negative equity reduce financial flexibility. A thin capital cushion increases vulnerability to revenue shocks, elevates refinancing or covenant risk, and raises the likelihood of dilutive raises or constrained strategic options over the medium term.
Biolidics Ltd. News
8YY FAQ
What was Biolidics Ltd.’s price range in the past 12 months?
Biolidics Ltd. lowest share price was S$0.02 and its highest was S$0.09 in the past 12 months.
What is Biolidics Ltd.’s market cap?
Biolidics Ltd.’s market cap is S$78.00M.
When is Biolidics Ltd.’s upcoming earnings report date?
Biolidics Ltd.’s upcoming earnings report date is Aug 07, 2026 which is in 78 days.
How were Biolidics Ltd.’s earnings last quarter?
Currently, no data Available
Is Biolidics Ltd. overvalued?
According to Wall Street analysts Biolidics Ltd.’s price is currently Overvalued.
Does Biolidics Ltd. pay dividends?
Biolidics Ltd. does not currently pay dividends.
What is Biolidics Ltd.’s EPS estimate?
Biolidics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biolidics Ltd. have?
Biolidics Ltd. has 1,733,441,800 shares outstanding.
What happened to Biolidics Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Biolidics Ltd.?
Currently, no hedge funds are holding shares in SG:8YY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biolidics Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Company Description
Biolidics Ltd.
Embracing Future Holdings Limited, a precision medicine medical technology company, focuses on developing a portfolio of diagnostic solutions in Japan, Hong Kong, Thailand, Malaysia, and the United States. It operates through Cancer, Infectious Diseases, and Laboratory Services segments. The company offers ClearCell FX1 System that includes Streck Cell-free DNA BCT and EDTA tubes, a fully automated device for cell retrieval that can separate wholly intact and viable circulating tumour cells, or CTCs from small amounts of blood; and CTChip FR1 biochip that isolate the CTCs from leukocytes. It also provides laboratory services. The company was formerly known as Biolidics Limited and changed its name to Embracing Future Holdings Limited in June 2025. The company was incorporated in 2009 and is based in Singapore.
Technical Analysis
Cordlife Group
―
ISEC Healthcare Ltd
―
Medtecs International Corporation Ltd.
―
AJJ Medtech Holdings Limited
―
Singapore Institute of Advanced Medicine Holdings Ltd.
―